Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, Inc., Merck KGaA, Pfizer, and AstraZeneca; collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SNDX
CUSIPN/A
Phone781-419-1400
Debt
Debt-to-Equity RatioN/A
Current Ratio7.06
Quick Ratio7.06
Price-To-Earnings
Trailing P/E Ratio-2.65
Forward P/E Ratio-2.11
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.11 million
Price / Sales89.94
Cash FlowN/A
Price / CashN/A
Book Value$4.28 per share
Price / Book1.79
Profitability
EPS (Most Recent Fiscal Year)($2.90)
Net Income$-60,800,000.00
Net Margins-3,081.07%
Return on Equity-67.69%
Return on Assets-52.09%
Miscellaneous
Employees44
Outstanding Shares24,710,000
Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions
What is Syndax Pharmaceuticals' stock symbol?
Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."
How were Syndax Pharmaceuticals' earnings last quarter?
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) posted its earnings results on Tuesday, May, 8th. The company reported ($0.79) earnings per share for the quarter, topping analysts' consensus estimates of ($0.96) by $0.17. The firm had revenue of $0.38 million for the quarter. Syndax Pharmaceuticals had a negative net margin of 3,081.07% and a negative return on equity of 67.69%. View Syndax Pharmaceuticals' Earnings History.
When is Syndax Pharmaceuticals' next earnings date?
What price target have analysts set for SNDX?
6 brokers have issued 12-month price targets for Syndax Pharmaceuticals' shares. Their forecasts range from $20.00 to $40.00. On average, they expect Syndax Pharmaceuticals' stock price to reach $26.1667 in the next year. View Analyst Ratings for Syndax Pharmaceuticals.
Who are some of Syndax Pharmaceuticals' key competitors?
Some companies that are related to Syndax Pharmaceuticals include AMAG Pharmaceuticals (AMAG), Theratechnologies (THERF), Amphastar Pharmaceuticals (AMPH), Dicerna Pharmaceuticals (DRNA), Urogen Pharma (URGN), Inflarx (IFRX), CannTrust (CNTTF), Arcus Biosciences (RCUS), Adamas Pharmaceuticals (ADMS), Odonate Therapeutics (ODT), Aduro BioTech (ADRO), GlycoMimetics (GLYC), Progenics Pharmaceuticals (PGNX), Prothena (PRTA) and Geron (GERN).
Who are Syndax Pharmaceuticals' key executives?
Syndax Pharmaceuticals' management team includes the folowing people:
- Dr. Briggs W. Morrison, CEO & Director (Age 58)
- Mr. Michael A. Metzger, Pres & COO (Age 47)
- Mr. Richard P. Shea, CFO, Treasurer & Principal Accounting Officer (Age 66)
- Dr. Michael L. Meyers M.D., Ph.D., Chief Medical Officer and Sr. VP (Age 67)
- Dr. Peter Ordentlich, Co-Founder & CTO (Age 49)
When did Syndax Pharmaceuticals IPO?
(SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.
Has Syndax Pharmaceuticals been receiving favorable news coverage?
News coverage about SNDX stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Syndax Pharmaceuticals earned a daily sentiment score of 0.11 on Accern's scale. They also assigned media stories about the company an impact score of 45.24 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Syndax Pharmaceuticals' major shareholders?
Syndax Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.17%), JPMorgan Chase & Co. (1.73%), Dimensional Fund Advisors LP (1.61%), Millennium Management LLC (1.38%), Point72 Asset Management L.P. (1.21%) and Sphera Funds Management LTD. (1.21%). View Institutional Ownership Trends for Syndax Pharmaceuticals.
Which major investors are selling Syndax Pharmaceuticals stock?
Which major investors are buying Syndax Pharmaceuticals stock?
SNDX stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Opaleye Management Inc., Dimensional Fund Advisors LP, BlackRock Inc., Asymmetry Capital Management L.P., Sphera Funds Management LTD., JPMorgan Chase & Co. and Sofinnova Ventures Inc. View Insider Buying and Selling for Syndax Pharmaceuticals.
How do I buy shares of Syndax Pharmaceuticals?
Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syndax Pharmaceuticals' stock price today?
One share of SNDX stock can currently be purchased for approximately $7.68.
How big of a company is Syndax Pharmaceuticals?
Syndax Pharmaceuticals has a market capitalization of $189.74 million and generates $2.11 million in revenue each year. The company earns $-60,800,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Syndax Pharmaceuticals employs 44 workers across the globe.
How can I contact Syndax Pharmaceuticals?
Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]
MarketBeat Community Rating for Syndax Pharmaceuticals (SNDX)
MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
